CA2181035A1 - Traitement therapeutique visant a inhiber la restenose vasculaire - Google Patents

Traitement therapeutique visant a inhiber la restenose vasculaire

Info

Publication number
CA2181035A1
CA2181035A1 CA002181035A CA2181035A CA2181035A1 CA 2181035 A1 CA2181035 A1 CA 2181035A1 CA 002181035 A CA002181035 A CA 002181035A CA 2181035 A CA2181035 A CA 2181035A CA 2181035 A1 CA2181035 A1 CA 2181035A1
Authority
CA
Canada
Prior art keywords
composition
mip
warm
blooded animal
rantes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002181035A
Other languages
English (en)
Inventor
Leon R. Lyle
Beth Thomas-Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2181035A1 publication Critical patent/CA2181035A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition appropriée pour être administrée à un animal à sang chaud. Cette composition comprend un oligonucléotide antisens par rapport à la famille de C-C chémokine, typifiée par les protéines MCP-1 et MIP-1 alpha, qui peut ou non être marqué par un radionucléide au moyen d'un ligand chélateur. Cette composition peut être administrée à un animal pour produire des images visuelles fiables des zones de resténose potentielle ou pour produire des effets thérapeutiques sur ces dernières.
CA002181035A 1994-01-14 1995-01-13 Traitement therapeutique visant a inhiber la restenose vasculaire Abandoned CA2181035A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18291794A 1994-01-14 1994-01-14
US08/182,917 1994-01-14

Publications (1)

Publication Number Publication Date
CA2181035A1 true CA2181035A1 (fr) 1995-07-20

Family

ID=22670615

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002181035A Abandoned CA2181035A1 (fr) 1994-01-14 1995-01-13 Traitement therapeutique visant a inhiber la restenose vasculaire

Country Status (4)

Country Link
EP (1) EP0802792A1 (fr)
JP (1) JPH09508358A (fr)
CA (1) CA2181035A1 (fr)
WO (1) WO1995019167A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2746815A1 (fr) * 1996-03-26 1997-10-03 Pasteur Institut Sequences en amont du gene sm 22, vecteurs les contenant et leurs utilisations therapeutiques, notamment dans le traitement des maladies vasculaires
US6736769B2 (en) 1996-04-17 2004-05-18 Olivier Bertrand Radioactivity local delivery system
AU2501197A (en) * 1996-04-17 1997-11-07 Olivier Bertrand Radioactivity local delivery system
US6673915B1 (en) 1996-09-30 2004-01-06 General Hospital Corporation Nucleic acid encoding monocyte chemotactic protein 4
US5821354A (en) * 1996-11-26 1998-10-13 Angiogene Inc. Radiolabeled DNA oligonucleotide and method of preparation
CA2618951A1 (fr) 2005-08-12 2007-02-22 Schering Corporation Fusions de mcp1
CN101174331B (zh) * 2006-11-01 2011-07-27 深圳市蓝韵实业有限公司 一种医学影像最大密度投影生成方法
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707440A (en) * 1984-01-30 1987-11-17 Enzo Biochem, Inc. Nucleic acid hybridization assay and detectable molecules useful in such assay
US5037630A (en) * 1985-01-14 1991-08-06 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4965392A (en) * 1987-03-26 1990-10-23 Neorx Corporation Chelating compounds for metal-radionuclide labeled proteins

Also Published As

Publication number Publication date
EP0802792A1 (fr) 1997-10-29
JPH09508358A (ja) 1997-08-26
WO1995019167A1 (fr) 1995-07-20

Similar Documents

Publication Publication Date Title
US5571713A (en) Therapeutic treatment for inhibiting vascular restenosis
AU783683B2 (en) VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
US5346696A (en) Asialoglycoprotein - conjugated medicinal agent
ES2303361T3 (es) Conjugados de interferon-alfa-polimero con actividad biologica potenciada y procedimientos de preparacion de los mismos.
TW593336B (en) Low-toxicity human interferon-alpha analog
JP2009089714A (ja) 標的化核酸構築物およびそれに関連する使用
JPH0770195A (ja) 糖修飾インターフェロン
CA2287538A1 (fr) Formes tronquees de proteines apparentees au facteur vegf
CA2304354A1 (fr) Procedes de modulation de la neovascularisation et/ou du developpement d'arteres collaterales et/ou d'autres arteres a partir de connexions arteriolaires existantes
WO2007082482B1 (fr) Nouveau composé de traitement de tumeur
JP2002534447A (ja) 感染及び炎症をターゲティング及び撮像するための化合物
US5980861A (en) Chelator compositions and methods of synthesis thereof
CA2181035A1 (fr) Traitement therapeutique visant a inhiber la restenose vasculaire
EP0478631B1 (fr) Agents de ciblage
CA2113206A1 (fr) Compositions de pf4 modifie et methodes d'utilisation
US8110552B2 (en) Antagonists against interaction of PF4 and RANTES
AU635721B2 (en) Targetting agents
Chakrabarti et al. Synthesis of novel peptide nucleic acid-peptide chimera for non-invasive imaging of cancer
WO2021175147A1 (fr) Conjugué antigène membranaire spécifique de la prostate-ligand de liaison et son utilisation
US6465613B1 (en) Hydrophilic somatostatin analogs
EP1229920A1 (fr) Therapie a base de 2-5a et d'interferon
AU677379B2 (en) Arteriosclerosis remedy
CN101119743B (zh) 免疫增强剂
US20210371478A1 (en) Generation of brain and spinal cord neurons, cardiac myocytes, and hepatocytes using reg peptides, peptidomimetics, small molecules and stimulatory antibodies to reg receptor
WO1995012414A1 (fr) Nouvelles compositions a base de pf4 modifie et procedes d'utilisation

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20000113